On the other hand, and with the aim of consolidating its presence in the North-American market, Infinitec has initiated a negotiation process with a Canadian biotech to adhere to a R&D&i project eligible for government funding by means of “Canadeka”, an institutional programme. <\/p>\n
Created in 2004 by Josep M. Borr\u00e0s and Alfons Hidalgo, Infinitec Actius is a company with shares held by both co-founding partners -who have a 42% stake of the shares – by the capital risk companies of Innova 31 (in which the Barcelona Science Park, the Polytechnical University of Catalonia, the Caixa d’Estalvis de Catalunya, Uni\u00f3n Interiores and EDM Holding have a stake) and by BCN Empr\u00e8n (36%). In 2008, in order to ensure the continuity of the project, Infinitec allowed a group of private investors to become shareholders of 20% of the company’s shares. <\/p>\n
The activity of Infinitec Activos is focused on the synthesis of biomolecules (peptides) and release systems, based on the fundamental principles of nanoscience, for the cosmetic industry. Its manufacturing plant is located in Montorn\u00e8s del Vall\u00e8s and its R&D&i laboratories in the bioincubator of the Barcelona Science Park. In spite of its young existence, this Catalan biotech is carrying out consolidated projects with renowned companies such as Est\u00e9e Lauder, La Prairie, L’Or\u00e9al, Unilever and Intercos, amongst others. <\/p>\n","protected":false},"excerpt":{"rendered":"